Advertisement

Most Promising Therapies in Interventional Cardiology

  • Mathieu Kerneis
  • Tarek Nafee
  • Megan K. Yee
  • Hassan A. Kazmi
  • Sudarshana Datta
  • Michel Zeitouni
  • M. Khurram Afzal
  • Mehrian Jafarizade
  • Sargun S. Walia
  • Iqra Qamar
  • Anmol Pitliya
  • Arzu Kalayci
  • Fahad Al Khalfan
  • C. Michael GibsonEmail author
New Therapies for Cardiovascular Disease (AA Bavry, Section Editor)
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease

Abstract

Purpose of Review

The last 40 years of clinical research in interventional cardiology were extraordinarily innovative. This article will review the most promising up and coming interventional cardiovascular therapies, with a primary focus on the treatment of coronary artery disease.

Recent Findings

From the first stent, to the first transcatheter aortic valve implantation (TAVI), and the left appendage closure technique, percutaneous interventions revolutionized the treatment of multiple diseases and dramatically improved the prognosis of many patients. While these advances have decreased the risk of mortality in some patients (such as ST-elevation myocardial infarction), 15% of acute coronary syndrome (ACS) patients still experience recurrent ischemic events within the first year, challenging us to develop new pharmaceutical targets and new devices.

Summary

The continued emergence of data supporting inflammation as a risk factor and pharmacologic target as well as data supporting the importance of cholesterol efflux have identified novel therapeutic targets that may play a major role in the improvement of prognosis of patients with coronary artery disease. In addition, novel medical devices are being developed to allow even earlier detection of acute cardiac events and to support high-risk percutaneous coronary interventions. Advances in computing and the ability to analyze large datasets will allow us to use artificial intelligence to augment the clinician patient experience, both in and out of the catheterization laboratory, with live procedural guidance as well as pre- and post-operative prognostication tools.

Keywords

Percutaneous coronary intervention Implantable device Acute coronary syndrome Coronary artery disease 

Abbreviations

ACS

Acute coronary syndrome

AMI

Acute myocardial infarction

CABG

Coronary artery bypass graft surgery

CAD

Coronary artery disease

BMS

Bare-metal stent

BVS

Bioresorbable vascular scaffold

DAPT

Dual anti-platelet therapy

DES

Drug-eluting stent

HDL

High-density lipoprotein

IVUS

Intravascular Ultra sound

LDL

Low-density lipoprotein

OCT

Optical coherence tomography

OMT

Optimal medical therapy

PCI

Percutaneous coronary intervention

STEMI

ST-elevation myocardial infarction

TAVI

Transcatheter aortic valve implantation

Notes

Compliance with Ethical Standards

Conflict of Interest

Mathieu Kerneis has received research grant from Federation Francaise de Cardiologie and Institut Servier.

C. Michael Gibson reports grants from Angel Medical Corporation; grants and personal fees from Bayer Corp., CSL Behring, Janssen Pharmaceuticals, and Johnson & Johnson Corporation; personal fees from The Medicines Company, Boston Clinical Research Institute, Cardiovascular Research Foundation, Eli Lilly and Company, Gilead Sciences, Inc., Novo Nordisk, Web MD, UpToDate in Cardiovascular Medicine, Portola Pharmaceuticals, Amarin Pharma, Amgen, Boehringer Ingelheim, Chiesi, Merck & Co, Inc., PharmaMar, Sanofi, Somahlution, St. Francis Hospital, Verreseon Corporation, Boston Scientific, Duke Clinical Research Institute, Impact Bio, LTD, MedImmune, Medtelligence, Microport, PERT Consortium, and nference; and non-financial support from Baim Institute.

Tarek Nafee has received research grant support and consulting fees from Portola Pharmaceuticals Inc.

Megan K. Yee, Hassan A. Kazmi, Sudarshana Datta, Michel Zeitouni, M. Khurram Afzal, Mehriam Jafarizade, Sargun S. Walia, Iqra Qamar, Anmol Pitliya, Arzu Kalayci, and Fahad Al Khalfan declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998–1006.Google Scholar
  2. 2.
    Nguyen V, Michel M, Eltchaninoff H, Gilard M, Dindorf C, Iung B, et al. Implementation of transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2018;71:1614–27.Google Scholar
  3. 3.
    Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–75.Google Scholar
  4. 4.
    Culler SD, Kugelmass AD, Brown PP, Reynolds MR, Simon AW. Trends in coronary revascularization procedures among Medicare beneficiaries between 2008 and 2012. Circulation. 2015;131:362–70 Lippincott Williams & Wilkins Hagerstown, MD, discussion370.Google Scholar
  5. 5.
    Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.Google Scholar
  6. 6.
    Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA American Medical Association. 2004;291:2727–33.CrossRefGoogle Scholar
  7. 7.
    Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–70.CrossRefGoogle Scholar
  8. 8.
    Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10 Massachusetts Medical Society.CrossRefGoogle Scholar
  9. 9.
    Ross R. Atherosclerosis—an inflammatory disease. Epstein FH, editor. N Engl J Med. 1999;340:115–26.CrossRefGoogle Scholar
  10. 10.
    Kalra A, Rehman H, Khera S, Thyagarajan B, Bhatt DL, Kleiman NS, et al. New-generation coronary stents: current data and future directions. Curr Atheroscler Rep Springer US. 2017;19:14.CrossRefGoogle Scholar
  11. 11.
    Johnson KW, Soto JT, Glicksberg BS, Shameer K, Miotto R, Ali M, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71:2668–79.CrossRefGoogle Scholar
  12. 12.
    Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.CrossRefGoogle Scholar
  13. 13.
    Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16 Massachusetts Medical Society.CrossRefGoogle Scholar
  14. 14.
    De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001 Massachusetts Medical Society.CrossRefGoogle Scholar
  15. 15.
    Angioplasty versus Medical Therapy for Single-Vessel Coronary Artery Disease. N Engl J Med. 1992;326:1632–4 Massachusetts Medical Society.Google Scholar
  16. 16.
    Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR, Krucoff MW, O'Neill WW, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007;50:1598–603.CrossRefGoogle Scholar
  17. 17.
    Al-Lamee R, Thompson D, Dehbi H-M, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40.CrossRefGoogle Scholar
  18. 18.
    Brown DL, Redberg RF. Last nail in the coffin for PCI in stable angina? Lancet. 2018;391:3–4.CrossRefGoogle Scholar
  19. 19.
    Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Outcomes with intravascular ultrasound-guided stent implantation: a meta-analysis of randomized trials in the era of drug-eluting stents. Circ Cardiovasc Interv. 2016;9:e003700 Lippincott Williams & Wilkins Hagerstown, MD.PubMedGoogle Scholar
  20. 20.•
    ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, et al. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. Am Heart J. 2018;201:124–35 This is the study design of the ISCHEMIA trial, that should provide in the next years a reliable answer to the question of whether a percutaneous coronary intervention should be performed among stable coronary artery disease patients. Google Scholar
  21. 21.
    James SK, Stenestrand U, Lindbäck J, Carlsson J, Scherstén F, Nilsson T, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. Massachusetts Medical Society. 2009;360:1933–45.CrossRefGoogle Scholar
  22. 22.
    Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, et al. Report of a European Society of Cardiology-European Association of percutaneous cardiovascular interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015;36:2608–20.Google Scholar
  23. 23.
    Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:1843–52.Google Scholar
  24. 24.
    Krackhardt F, Kočka V, Waliszewski MW, Utech A, Lustermann M, Hudec M, et al. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart. 2017;4:e000592.Google Scholar
  25. 25.
    Chen W, Habraken TCJ, Hennink WE, Kok RJ. Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjug Chem. 2015;26:1277–88.CrossRefGoogle Scholar
  26. 26.
    Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. Massachusetts Medical Society. 2015;373:1905–15.CrossRefGoogle Scholar
  27. 27.
    Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 2017;70:2852–62.Google Scholar
  28. 28.
    Waksman R. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;377:1790–1.CrossRefGoogle Scholar
  29. 29.
    Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056–61.CrossRefGoogle Scholar
  30. 30.
    Elmariah S, Jang I-K. Acute stent thrombosis: technical complication or inadequate antithrombotic therapy? An optical coherence tomography study. JACC Cardiovasc Interv. 2012;5:e3–4.CrossRefGoogle Scholar
  31. 31.
    Koskinas KC, Nakamura M, Räber L, Colleran R, Kadota K, Capodanno D, et al. Current use of intracoronary imaging in interventional practice—results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) clinical practice survey. EuroIntervention Europa Digital & Publishing. 2018;14:e475–84.CrossRefGoogle Scholar
  32. 32.
    Gan Y, Tsay D, Amir SB, Marboe CC, Hendon CP. Automated classification of optical coherence tomography images of human atrial tissue. J Biomed Opt. International Society for Optics and Photonics. 2016;21:101407.CrossRefGoogle Scholar
  33. 33.
    Karimi Galougahi K, Zalewski A, Leon MB, Karmpaliotis D, Ali ZA. Optical coherence tomography-guided percutaneous coronary intervention in pre-terminal chronic kidney disease with no radio-contrast administration. Eur Heart J. 2016;37:1059–9.Google Scholar
  34. 34.
    Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012:2569–619.Google Scholar
  35. 35.
    Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the global registry of acute coronary events. Chest. 2004;126:461–9.Google Scholar
  36. 36.
    Rogers T, Steinvil A, Torguson R, Waksman R. The AngelMed Guardian system: is there a role for implantable devices for early detection of coronary artery occlusion? Cardiovasc Revasc Med. Elsevier. 2016;17:522–7.CrossRefGoogle Scholar
  37. 37.
    Navarese EP, Robinson JG, Kowalewski M, Kołodziejczak M, Andreotti F, Bliden K, et al. Association between baseline LDL-C level and Total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA American Medical Association. 2018;319:1566–79.CrossRefGoogle Scholar
  38. 38.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Mass Med Soc. 2009;350:1495–504.  https://doi.org/10.1056/NEJMoa040583.CrossRefGoogle Scholar
  39. 39.
    Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. Mass Med Soc. 2015;372:2387–97.  https://doi.org/10.1056/NEJMoa1410489.CrossRefGoogle Scholar
  40. 40.
    Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823–8.CrossRefGoogle Scholar
  41. 41.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. Massachusetts Medical Society. 2017;376:1713–22.CrossRefGoogle Scholar
  42. 42.
    Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.Google Scholar
  43. 43.
    Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69:471–82.Google Scholar
  44. 44.
    Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682–9.Google Scholar
  45. 45.
    Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137:338–50.Google Scholar
  46. 46.
    Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005;26:890–6.Google Scholar
  47. 47.
    Duffy D, Holmes DN, Roe MT, Peterson ED. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. Am Heart J. 2012;163:705–13.CrossRefGoogle Scholar
  48. 48.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. Massachusetts Medical Society. 2012;367:2089–99.CrossRefGoogle Scholar
  49. 49.
    Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–42.Google Scholar
  50. 50.
    Siddiqi HK, Kiss D, Rader D. HDL-cholesterol and cardiovascular disease: rethinking our approach. Curr Opin Cardiol. 2015;30:536–42.CrossRefGoogle Scholar
  51. 51.
    Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, et al. Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a Phase 2a randomized clinical trial. J Am Heart Assoc. American Heart Association, Inc. 2015;4:e002171.CrossRefGoogle Scholar
  52. 52.
    Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.CrossRefGoogle Scholar
  53. 53.
    Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res. Lippincott Williams & Wilkins Hagerstown, MD. 2014;114:1733–42.CrossRefGoogle Scholar
  54. 54.••
    Gibson MC, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016;134:1918–30 This trial is the first stone of new HDL hypothesis, suggesting that improving that HDL function may safely reduce the risk of ischemic outcomes among patients with MI. Google Scholar
  55. 55.
    Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation Lippincott Williams & Wilkins. 2004;109:II2–10.PubMedGoogle Scholar
  56. 56.
    Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. Massachusetts Medical Society. 2008;359:2195–207.CrossRefGoogle Scholar
  57. 57.••
    Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31 Massachusetts Medical Society, This trial is the proof of concept of the inflammatory hypothesis in coronary artery disease (CAD). Administration of canakinumab, an IL 1 inhibitor, was associated with a reduction of the ischemic events among a large population of CAD patients. Google Scholar
  58. 58.
    Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling trial [VCU-ART] pilot study). Am J Cardiol. 2010;105:1371–1.Google Scholar
  59. 59.
    Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra remodeling trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394–400.CrossRefGoogle Scholar
  60. 60.
    Renné T, Oschatz C, Seifert S, Müller F, Antovic J, Karlman M, et al. Factor XI deficiency in animal models. J Thromb Haemost Wiley/Blackwell (10.1111). 2009;7(Suppl 1):79–83.CrossRefGoogle Scholar
  61. 61.
    Renné T, Pozgajová M, Grüner S, Schuh K, Pauer H-U, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271–81.Google Scholar
  62. 62.
    Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. Massachusetts Medical Society. 2015;372:232–40.CrossRefGoogle Scholar
  63. 63.
    Al'Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. Eur Heart J. 2nd ed. 2018;359:1675.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mathieu Kerneis
    • 1
    • 2
  • Tarek Nafee
    • 1
  • Megan K. Yee
    • 1
  • Hassan A. Kazmi
    • 1
  • Sudarshana Datta
    • 1
  • Michel Zeitouni
    • 2
  • M. Khurram Afzal
    • 1
  • Mehrian Jafarizade
    • 1
  • Sargun S. Walia
    • 1
  • Iqra Qamar
    • 1
  • Anmol Pitliya
    • 1
  • Arzu Kalayci
    • 1
  • Fahad Al Khalfan
    • 1
  • C. Michael Gibson
    • 1
    Email author
  1. 1.PERFUSE Study Group, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA
  2. 2.ACTION Study Group, INSERM UMR_S 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP)Sorbonne Université - Univ Paris 06 (UPMC)ParisFrance

Personalised recommendations